Clinical Trial Update: Pasireotide Treatment for Neuroendocrine Tumor [Phase 4]

View source ↗

Summary

Phase 4 trial of pasireotide for gastro-enteropancreatic neuroendocrine tumor was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastro-enteropancreatic Neuroendocrine Tumor

Drugs mentioned

• Pasireotide (pasireotide)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Gastro-enteropancreatic Neuroendocrine Tumor | Phase 4 | Status: WITHDRAWN